000			02783nam a22004335i 4500
001			u372173
003			SIRSI
005			20160812084045.0
007			cr nn 008mamaa
008			110506s2011 xxu| s |||| 0|eng d
020			_a9781441984593 _9978-1-4419-8459-3
040			_cMX-MeUAM
050		4	_aRC261-271
082	0	4	_a614.5999 _223
100	1		_aSaha, Vaskar. _eeditor.
245	1	0	_aNew Agents for the Treatment of Acute Lymphoblastic Leukemia _h[recurso electrónico] / _cedited by Vaskar Saha, Pamela Kearns.
264		1	_aNew York, NY : _bSpringer New York, _c2011.
300			_aXVIII, 338 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aThe need for new agents -- Identifying pre-clinical agents -- Pre-clinical evaluation -- Design of early phase trials -- Strategies for trial design and analyses -- Overview on Molecular and Animal models of ALL -- Apoptosis, BCL2 -- Targeting Stem Cells -- Nucleoside Analogues -- Flt3 Inhibitors -- Tyrosine Kinase Inhibitors -- Monoclonal Antibodies -- Proteasome inhibitors -- Targeting epigenetic pathways in ALL.- Incorporating new therapies in frontline protocols.-.
520			_aNew Agents for the Treatment of Acute Lymphoblastic Leukaemia (ALL), examines the strategies for the use of new agents as well as possible targets of therapy in this disease. Though associated with high cure rates, relapsed disease has a poor outcome. Moreover, therapy is unduly prolonged and toxic. For over 4 decades, no new drugs have been available and now we have a surfeit. The challenge is to design trials to evaluate the potential efficacy of non-targeted therapy in a disease with good outcome. An increasing number of pathways, amenable to targeted therapy are also being identified. The heterogeneity of ALL suggests that targeted therapy at the moment will need to be tailored to the patient. How then can such drugs be evaluated within conventional clinical trials? These are the crossroads we have reached in acute lymphoblastic leukaemia and this book discusses and proposes some solutions to these issues.
650		0	_aMedicine.
650		0	_aOncology.
650		0	_aToxicology.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
650	2	4	_aPharmacology/Toxicology.
700	1		_aKearns, Pamela. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9781441984586
856	4	0	_zLibro electrónico _uhttp://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-1-4419-8459-3
596			_a19
942			_cLIBRO_ELEC
999			_c200053 _d200053